NEW YORK (GenomeWeb) — IntegraGen announced today that it is collaborating with investigators from the FIRE-3 clinical trial to study the use of a microRNA biomarker to predict clinical outcomes in metastatic colorectal cancer patients treated with anti-EGFR therapies.

The FIRE-3 study is a Phase III trial comparing FOLFIRI — Camptosar (irinotecan) with fluorouracil and folinic acid — in combination with either Erbitux (cetuximab) or Avastin (bevacizumab) as a first-line therapy in patients with KRAS exon 2 wild-type stage IV colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.